Eventually, he began to study an antibody called Ibalizumab that was designed to block HIV from attaching to CD4, the primary receptor used by the virus to infect a cell.
One possible cause of their vulnerability is that the virus has evolved around its problem, and found a way to use a slightly different chemokine receptor as a way into its target macrophages.